questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Hémoprotéines
Cytochromes
Cytochrome P-450 enzyme system
Famille-26 de cytochromes P450
Famille-26 de cytochromes P450 : Questions médicales fréquentes
Termes MeSH sélectionnés :
Attention Deficit and Disruptive Behavior Disorders
Diagnostic
5
Cytochrome P450
Tests génétiques
Cytochrome P450
Métabolites
Troubles hormonaux
Symptômes cliniques
Imagerie médicale
Cytochrome P450
Antécédents médicaux
Traitement médicamenteux
Symptômes
5
Troubles métaboliques
Déséquilibres hormonaux
Douleur
Déséquilibres hormonaux
Éruptions cutanées
Déséquilibres métaboliques
Troubles de l'humeur
Déséquilibres hormonaux
Fertilité
Niveaux hormonaux
Prévention
5
Prévention
Alimentation saine
Tests génétiques
Prévention
Médicaments
Cytochrome P450
Habitudes de vie
Cytochrome P450
Traitements
5
Thérapies hormonales
Ajustements médicamenteux
Alimentation équilibrée
Métabolisme hormonal
Médicaments
Déséquilibres hormonaux
Thérapie génique
Cytochrome P450
Traitements personnalisés
Cytochrome P450
Complications
5
Complications
Troubles métaboliques
Maladies chroniques
Diabète
Qualité de vie
Complications
Réversibilité
Complications
Facteurs de risque
5
Facteurs de risque
Antécédents familiaux
Âge
Changements hormonaux
Mode de vie
Dysfonctionnement
Facteurs environnementaux
Cytochrome P450
Maladies préexistantes
Cytochrome P450
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Famille-26 de cytochromes P450 : Questions médicales les plus fréquentes",
"headline": "Famille-26 de cytochromes P450 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Famille-26 de cytochromes P450 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-04",
"dateModified": "2025-03-29",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Famille-26 de cytochromes P450"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Cytochrome P-450 enzyme system",
"url": "https://questionsmedicales.fr/mesh/D003577",
"about": {
"@type": "MedicalCondition",
"name": "Cytochrome P-450 enzyme system",
"code": {
"@type": "MedicalCode",
"code": "D003577",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.422.220.453"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Retinoic acid 4-hydroxylase",
"alternateName": "Retinoic Acid 4-Hydroxylase",
"url": "https://questionsmedicales.fr/mesh/D000072516",
"about": {
"@type": "MedicalCondition",
"name": "Retinoic acid 4-hydroxylase",
"code": {
"@type": "MedicalCode",
"code": "D000072516",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.422.220.453.498.500"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Famille-26 de cytochromes P450",
"alternateName": "Cytochrome P450 Family 26",
"code": {
"@type": "MedicalCode",
"code": "D000072500",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "David R Nelson",
"url": "https://questionsmedicales.fr/author/David%20R%20Nelson",
"affiliation": {
"@type": "Organization",
"name": "Department of Microbiology, Immunology and Biochemistry, University of Tennessee, Memphis, TN 38163, USA."
}
},
{
"@type": "Person",
"name": "F Peter Guengerich",
"url": "https://questionsmedicales.fr/author/F%20Peter%20Guengerich",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0146. Electronic address: f.guengerich@vanderbilt.edu."
}
},
{
"@type": "Person",
"name": "Donghak Kim",
"url": "https://questionsmedicales.fr/author/Donghak%20Kim",
"affiliation": {
"@type": "Organization",
"name": "Department of Biological Sciences, Konkuk University, 120 Neungdongro, Gwangjjn-Gu, Seoul, 05025 Republic of Korea."
}
},
{
"@type": "Person",
"name": "Emily E Scott",
"url": "https://questionsmedicales.fr/author/Emily%20E%20Scott",
"affiliation": {
"@type": "Organization",
"name": "Program in Biophysics, University of Michigan, Ann Arbor, Michigan 48109; Departments of Medicinal Chemistry and Pharmacology, University of Michigan, Ann Arbor, Michigan 48109. Electronic address: scottee@umich.edu."
}
},
{
"@type": "Person",
"name": "Vitchan Kim",
"url": "https://questionsmedicales.fr/author/Vitchan%20Kim",
"affiliation": {
"@type": "Organization",
"name": "Department of Biological Sciences, Konkuk University, 120 Neungdongro, Gwangjjn-Gu, Seoul, 05025 Republic of Korea."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Online parent training platform for complementary treatment of disruptive behavior disorders in attention deficit hyperactivity disorder: A randomized controlled trial protocol.",
"datePublished": "2022-10-27",
"url": "https://questionsmedicales.fr/article/36301983",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0272516"
}
},
{
"@type": "ScholarlyArticle",
"name": "Examining attention-deficit/hyperactivity disorder and related behavioral disorders by fertility treatment exposure in a prospective cohort.",
"datePublished": "2023-03-25",
"url": "https://questionsmedicales.fr/article/36972758",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.annepidem.2023.03.006"
}
},
{
"@type": "ScholarlyArticle",
"name": "Attachment in adolescents with attention deficit hyperactivity disorder and oppositional defiant disorder.",
"datePublished": "2022-06-30",
"url": "https://questionsmedicales.fr/article/36342984",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.12740/PP/OnlineFirst/130366"
}
},
{
"@type": "ScholarlyArticle",
"name": "The functioning of families of teens with attention deficit hyperactivity disorder and oppositional defiant disorder.",
"datePublished": "2022-08-31",
"url": "https://questionsmedicales.fr/article/37074835",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.12740/PP/OnlineFirst/128372"
}
},
{
"@type": "ScholarlyArticle",
"name": "Understanding Attentional Functioning in Adult Attention Deficit Hyperactivity Disorder-Could This Improve Diagnostic Specificity?",
"datePublished": "2023-03-14",
"url": "https://questionsmedicales.fr/article/36981985",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijerph20065077"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Hémoprotéines",
"item": "https://questionsmedicales.fr/mesh/D006420"
},
{
"@type": "ListItem",
"position": 5,
"name": "Cytochromes",
"item": "https://questionsmedicales.fr/mesh/D003580"
},
{
"@type": "ListItem",
"position": 6,
"name": "Cytochrome P-450 enzyme system",
"item": "https://questionsmedicales.fr/mesh/D003577"
},
{
"@type": "ListItem",
"position": 7,
"name": "Famille-26 de cytochromes P450",
"item": "https://questionsmedicales.fr/mesh/D000072500"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Famille-26 de cytochromes P450 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Famille-26 de cytochromes P450",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-14",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Famille-26 de cytochromes P450",
"description": "Comment diagnostiquer une dysfonction des cytochromes P450 26 ?\nQuels tests sont utilisés pour évaluer l'activité des CYP26 ?\nLes symptômes cliniques aident-ils au diagnostic ?\nPeut-on utiliser l'imagerie pour le diagnostic ?\nLes antécédents médicaux sont-ils importants ?",
"url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Famille-26 de cytochromes P450",
"description": "Quels sont les symptômes d'une anomalie des CYP26 ?\nLes anomalies des CYP26 causent-elles des douleurs ?\nY a-t-il des symptômes cutanés associés ?\nLes troubles de l'humeur sont-ils liés aux CYP26 ?\nLes anomalies des CYP26 affectent-elles la fertilité ?",
"url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Famille-26 de cytochromes P450",
"description": "Comment prévenir les dysfonctionnements des CYP26 ?\nLes tests génétiques peuvent-ils prévenir des problèmes ?\nL'évitement de certains médicaments est-il conseillé ?\nLe suivi médical régulier est-il important ?\nLes habitudes de vie influencent-elles la santé des CYP26 ?",
"url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Famille-26 de cytochromes P450",
"description": "Quels traitements sont disponibles pour les dysfonctionnements des CYP26 ?\nLes modifications alimentaires aident-elles ?\nDes médicaments spécifiques sont-ils utilisés ?\nLa thérapie génique est-elle une option ?\nLes traitements sont-ils personnalisés ?",
"url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Famille-26 de cytochromes P450",
"description": "Quelles complications peuvent survenir avec les anomalies des CYP26 ?\nLes anomalies des CYP26 peuvent-elles causer des maladies chroniques ?\nY a-t-il un risque accru de cancer ?\nLes complications affectent-elles la qualité de vie ?\nLes complications sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Famille-26 de cytochromes P450",
"description": "Quels sont les facteurs de risque pour les anomalies des CYP26 ?\nL'âge influence-t-il le risque ?\nLe mode de vie joue-t-il un rôle ?\nLes facteurs environnementaux sont-ils importants ?\nLes maladies préexistantes augmentent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction des cytochromes P450 26 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses de sang peuvent aider à diagnostiquer les anomalies."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité des CYP26 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques et des dosages de métabolites spécifiques sont utilisés."
}
},
{
"@type": "Question",
"name": "Les symptômes cliniques aident-ils au diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme des troubles hormonaux peuvent indiquer une dysfonction."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie pour le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie n'est pas couramment utilisée pour diagnostiquer les CYP26."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux sont-ils importants ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les antécédents de traitement médicamenteux peuvent influencer le diagnostic."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une anomalie des CYP26 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes incluent des troubles métaboliques et des déséquilibres hormonaux."
}
},
{
"@type": "Question",
"name": "Les anomalies des CYP26 causent-elles des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent entraîner des douleurs liées à des déséquilibres hormonaux."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes cutanés associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des éruptions cutanées peuvent survenir en raison de déséquilibres métaboliques."
}
},
{
"@type": "Question",
"name": "Les troubles de l'humeur sont-ils liés aux CYP26 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles de l'humeur peuvent être liés à des déséquilibres hormonaux."
}
},
{
"@type": "Question",
"name": "Les anomalies des CYP26 affectent-elles la fertilité ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent affecter la fertilité en perturbant les niveaux hormonaux."
}
},
{
"@type": "Question",
"name": "Comment prévenir les dysfonctionnements des CYP26 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation saine et un suivi médical régulier peuvent aider à prévenir."
}
},
{
"@type": "Question",
"name": "Les tests génétiques peuvent-ils prévenir des problèmes ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent identifier les risques avant l'apparition des symptômes."
}
},
{
"@type": "Question",
"name": "L'évitement de certains médicaments est-il conseillé ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, éviter les médicaments connus pour interférer avec les CYP26 peut être bénéfique."
}
},
{
"@type": "Question",
"name": "Le suivi médical régulier est-il important ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier permet de détecter précocement les anomalies."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie influencent-elles la santé des CYP26 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes de vie saines peuvent améliorer la fonction des CYP26."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les dysfonctionnements des CYP26 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des thérapies hormonales et des ajustements médicamenteux."
}
},
{
"@type": "Question",
"name": "Les modifications alimentaires aident-elles ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation équilibrée peut soutenir le métabolisme hormonal."
}
},
{
"@type": "Question",
"name": "Des médicaments spécifiques sont-ils utilisés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments ciblant les déséquilibres hormonaux peuvent être prescrits."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est encore en recherche pour traiter les anomalies des CYP26."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements sont souvent adaptés en fonction des besoins individuels."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les anomalies des CYP26 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles métaboliques graves et des déséquilibres hormonaux."
}
},
{
"@type": "Question",
"name": "Les anomalies des CYP26 peuvent-elles causer des maladies chroniques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent contribuer à des maladies chroniques comme le diabète."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de cancer ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines anomalies peuvent augmenter le risque de cancers hormonodépendants."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent significativement altérer la qualité de vie."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les anomalies des CYP26 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux et l'exposition à certains médicaments."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque peut augmenter avec l'âge en raison de changements hormonaux."
}
},
{
"@type": "Question",
"name": "Le mode de vie joue-t-il un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie malsain peut augmenter le risque de dysfonctionnement."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux sont-ils importants ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des toxines environnementales peut affecter les CYP26."
}
},
{
"@type": "Question",
"name": "Les maladies préexistantes augmentent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies peuvent prédisposer à des anomalies des CYP26."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 29/03/2025
Contenu vérifié selon les dernières recommandations médicales
10 publications dans cette catégorie
Affiliations :
Department of Microbiology, Immunology and Biochemistry, University of Tennessee, Memphis, TN 38163, USA.
5 publications dans cette catégorie
Affiliations :
Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0146. Electronic address: f.guengerich@vanderbilt.edu.
Publications dans "Famille-26 de cytochromes P450" :
4 publications dans cette catégorie
Affiliations :
Department of Biological Sciences, Konkuk University, 120 Neungdongro, Gwangjjn-Gu, Seoul, 05025 Republic of Korea.
Publications dans "Famille-26 de cytochromes P450" :
3 publications dans cette catégorie
Affiliations :
Program in Biophysics, University of Michigan, Ann Arbor, Michigan 48109; Departments of Medicinal Chemistry and Pharmacology, University of Michigan, Ann Arbor, Michigan 48109. Electronic address: scottee@umich.edu.
Publications dans "Famille-26 de cytochromes P450" :
3 publications dans cette catégorie
Affiliations :
Department of Biological Sciences, Konkuk University, 120 Neungdongro, Gwangjjn-Gu, Seoul, 05025 Republic of Korea.
Publications dans "Famille-26 de cytochromes P450" :
3 publications dans cette catégorie
Affiliations :
Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan.
Publications dans "Famille-26 de cytochromes P450" :
2 publications dans cette catégorie
Affiliations :
College of Plant Protection, Hunan Agricultural University, Changsha 410125, P. R. China.
State Key Laboratory of Vegetable Biobreeding, Department of Plant Protection, Institute of Vegetables and Flowers, Chinese Academy of Agricultural Sciences, Beijing 100081, China.
Publications dans "Famille-26 de cytochromes P450" :
2 publications dans cette catégorie
Affiliations :
Department of Biological Sciences, Konkuk University, 120 Neungdongro, Gwangjjn-Gu, Seoul, 05025 Republic of Korea.
Publications dans "Famille-26 de cytochromes P450" :
2 publications dans cette catégorie
Affiliations :
Department of Biological Sciences, Konkuk University, 120 Neungdongro, Gwangjjn-Gu, Seoul, 05025 Republic of Korea.
Publications dans "Famille-26 de cytochromes P450" :
2 publications dans cette catégorie
Affiliations :
Department of Biological Sciences, Konkuk University, 120 Neungdongro, Gwangjjn-Gu, Seoul, 05025 Republic of Korea.
Publications dans "Famille-26 de cytochromes P450" :
2 publications dans cette catégorie
Affiliations :
Manchester Institute of Biotechnology and Department of Chemical Engineering and Analytical Science, the University of Manchester, 131 Princess Street, Manchester M1 7DN, UK.
Publications dans "Famille-26 de cytochromes P450" :
2 publications dans cette catégorie
Affiliations :
Manchester Institute of Biotechnology and Department of Chemical Engineering and Analytical Science, the University of Manchester, 131 Princess Street, Manchester M1 7DN, UK.
Publications dans "Famille-26 de cytochromes P450" :
2 publications dans cette catégorie
Affiliations :
Biology Department, Woods Hole Oceanographic Institution, Woods Hole, MA 02543.
Institute of Life Science, Swansea University Medical School, Swansea University, Swansea, SA2 8PP Wales, United Kingdom.
Publications dans "Famille-26 de cytochromes P450" :
2 publications dans cette catégorie
Affiliations :
Biology Department, Woods Hole Oceanographic Institution, Woods Hole, MA 02543.
Publications dans "Famille-26 de cytochromes P450" :
2 publications dans cette catégorie
Affiliations :
Department of Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan, USA.
Publications dans "Famille-26 de cytochromes P450" :
2 publications dans cette catégorie
Affiliations :
Center for Toxicogenomics and Human Health (ToxOmics), Genetics, Oncology and Huma Toxicology, NOVA Medical School/Faculty of Medical Sciences, Universidade NOVA de Lisboa, 1169-056 Lisboa, Portugal.
Publications dans "Famille-26 de cytochromes P450" :
2 publications dans cette catégorie
Affiliations :
Center for Toxicogenomics and Human Health (ToxOmics), Genetics, Oncology and Huma Toxicology, NOVA Medical School/Faculty of Medical Sciences, Universidade NOVA de Lisboa, 1169-056 Lisboa, Portugal.
Publications dans "Famille-26 de cytochromes P450" :
2 publications dans cette catégorie
Affiliations :
Center for Toxicogenomics and Human Health (ToxOmics), Genetics, Oncology and Huma Toxicology, NOVA Medical School/Faculty of Medical Sciences, Universidade NOVA de Lisboa, 1169-056 Lisboa, Portugal.
Publications dans "Famille-26 de cytochromes P450" :
2 publications dans cette catégorie
Affiliations :
Department of Biochemistry and Microbiology, Faculty of Science, Agriculture and Engineering, University of Zululand, KwaDlangezwa 3886, South Africa.
Publications dans "Famille-26 de cytochromes P450" :
2 publications dans cette catégorie
Affiliations :
Food Chemistry Section, Division of Hygienic Chemistry, Osaka Institute of Public Health, Higashinari-ku, Osaka 537-0025, Japan.
Publications dans "Famille-26 de cytochromes P450" :
Attention Deficit/Hyperactivity Disorder (ADHD) is associated with a diversity of impairments and Oppositional Defiant Disorder (ODD) is a very frequent comorbidity. Parent Training, as an evidence-ba...
Patients and their families will be screened upon their entry into the Research Center of Impulsivity and Attention (NITIDA) at UFMG-Brazil. Ninety families whose children are male, between 6-12 years...
This clinical trial intends to verify the effects of a new, online, model of an evidence-based intervention, which would allow a wider access in the Brazilian context....
Registered on Brazilian Registry of Clinical Trials (ReBEC). Number: RBR-6cvc85. July 24th (2020) 05:35 pm....
To evaluate whether underlying infertility and mode of conception are associated with childhood behavioral disorders....
Oversampling on fertility treatment exposure using vital records, the Upstate KIDS Study followed 2057 children (of 1754 mothers) from birth to 11 years. Type of fertility treatment and time to pregna...
Children conceived with fertility treatment (34%) did not have an increased risk of attention-deficit/hyperactivity disorder (aRR): 1.21; 95% CI: 0.88, 1.65), or conduct or oppositional defiant disord...
Underlying infertility or its treatment was not associated with risk of attention-deficit/hyperactivity disorder. Observations of increased anxiety or depression require replication....
To assess attachment styles among adolescents (13-16 years) with ADHD or ADHD and oppositional defiant disorders (ODD)....
The Parents and Peers Attachment (IPPA) and the Parent Bonding Questionnaire (PBI) were used in three groups of teenagers raised in biological families: (1) ADHD/ODD group (n = 40), (2) ADHD group (n ...
Parental attachment styles in the area of "Trust", "Communication" and "Alienation" (IPPA), and "Care" and "Control" (PBI) in the ADHD/ODD group differ significantly compared to the control group. Tee...
The attachment style is significantly different in adolescents diagnosed with ADHD and ODD than in adolescents with only ADHD. In the ADHD/ODD group and the ADHD group, unlike in the group of adolesce...
Comparison of the functioning of families of teens (13-16 years) with the diagnosis of attention deficit hyperactivity disorder (ADHD) or ADHD and oppositional defiant disorder (ODD)....
Assessment using the Family Assessment Questionnaire in three groups of adolescents growing up in biological families: (1) ADHD/ODD group (n = 40), (2) ADHD group (n = 40) and (3) group C (control gro...
Mothers, fathers and adolescents from the ADHD/ODD group scored significantly lower in all important aspects of family functioning compared to the control group. In the ADHD group, less favorable moth...
The functioning of families of patients with ADHD and ODD, and families of patients with ADHD significantly differs in all or most of the examined dimensions compared with families of people without d...
The diagnostic criteria for attention deficit hyperactivity disorder (ADHD) reflect the behavioural and functional outcomes of cognitive processes. Historically they have been based on external observ...
The impairment of executive functions (EFs) in attention-deficit/hyperactivity disorder (ADHD) might vary from one individual to another, indicating high heterogeneity. Comorbidity may contribute to t...
This cohort study aimed to examine the association between prenatal exposure to illicit drugs and neurodevelopmental and disruptive behavioral disorders (DBD) in children aged 7-12 years, using data f...
Child-centered play therapy (CCPT) is a practical and recommended non-medication intervention for children with Attention-deficit/hyperactivity disorder (ADHD) but the mechanism in between is unclear....
This study proposed to examine the effectiveness of CCPT on neuropsychological deficits and behavioral symptoms in ADHD....
Participants with ADHD diagnosis were referred from senior child and adolescent psychiatrists, and typical developmental children (TD) were recruited from community as a control group. All participant...
Total 52 participants were recruited (17 with ADHD and 35 typically developed children, TD). The results showed that overall the ADHD groups had worse neuropsychological performance and more behaviour...
Cross-sectional studies have demonstrated associations between screen time and disruptive behavior disorders (conduct disorder and oppositional defiant disorder); however, prospective associations rem...
We analyzed data from the Adolescent Brain Cognitive Development (ABCD) Study (N = 11,875). Modified Poisson regression analyses were conducted to estimate the associations between baseline child-repo...
Participants reported an average of 4 hr of total screen time per day at baseline. Each hour of total screen time per day was prospectively associated with a 7% higher prevalence of conduct disorder (...
Higher screen time was prospectively associated with a higher prevalence of new-onset disruptive behavior disorders. The strongest association was between social media and conduct disorder, indicating...
Caring for children with attention-deficit/hyperactivity disorder (CADHD) is stressful for caregivers. Identifying factors related to parenting stress in caregivers of CADHD can facilitate the develop...